Location History:
- München, DE (2015)
- Munich, DE (2011 - 2021)
- Planegg, DE (2021)
Company Filing History:
7 out of 88 
2 out of 323 
1 out of 721 
Years Active: 2011-2021
Title: Innovations and Contributions of Inventor Stefan Steidl
Introduction
Stefan Steidl is a prominent inventor based in Munich, Germany, recognized for his significant contributions to the field of biotechnology. With a total of seven patents to his name, Steidl focuses on innovative solutions to treat complex medical conditions.
Latest Patents
Among his notable inventions are patents related to nucleic acid encoding anti-GM-CSF antibodies. This invention describes recombinant antigen-binding regions, antibodies, and functional fragments that specifically target GM-CSF, a crucial factor in various inflammatory disorders. These antibodies have potential applications not only in treating inflammatory diseases, such as rheumatoid arthritis, but also in diagnostic settings to understand the role of GM-CSF in disease progression. Furthermore, his invention includes nucleic acid sequences encoding the antibodies, vectors for their delivery, and pharmaceutical compositions along with kits for usage instructions. Another significant patent focuses on using anti-GM-CSF antibodies, specifically MOR103, in treating rheumatoid arthritis effectively in a clinical context.
Career Highlights
Stefan Steidl has garnered experience working with esteemed organizations, including Morphosys AG and the University of Melbourne. His work at these institutions has allowed him to delve into the realms of research and development, facilitating the advancement of medical science.
Collaborations
Steidl has had fruitful collaborations with notable colleagues, including Elisabeth Thomassen-Wolf and John Allan Hamilton. Their joint efforts have further propelled innovative research in the field of biotechnology.
Conclusion
Stefan Steidl's work exemplifies the intersection of innovation and practical application in medicine. His contributions, particularly concerning anti-GM-CSF antibodies, show promise in addressing severe inflammatory diseases. As he continues to develop groundbreaking solutions, Steidl's impact on biopharmaceuticals and therapeutic research remains influential and significant.